Emicizumab should be prescribed independent of immune tolerance induction

por Le Quellec, Sandra, Negrier, Claude
Publicado en Blood Adv (2018)

Dose tailoring of human cell line‐derived recombinant factor VIII simoctocog alfa: Using a limited sampling strategy in patients with severe haemophilia A

por Delavenne, Xavier, Dargaud, Yesim, Ollier, Edouard, Négrier, Claude
Publicado en Br J Clin Pharmacol (2019)

Evaluation of early musculoskeletal disease in patients with haemophilia: results from an expert consensus

por Seuser, Axel, Djambas Khayat, Claudia, Negrier, Claude, Sabbour, Adly, Heijnen, Lily
Publicado en Blood Coagul Fibrinolysis (2018)

Emerging Immunogenicity and Genotoxicity Considerations of Adeno-Associated Virus Vector Gene Therapy for Hemophilia

por Monahan, Paul E., Négrier, Claude, Tarantino, Michael, Valentino, Leonard A., Mingozzi, Federico
Publicado en J Clin Med (2021)

Thrombin generation and whole blood viscoelastic assays in the management of hemophilia: current state of art and future perspectives

por Young, Guy, Sørensen, Benny, Dargaud, Yesim, Negrier, Claude, Brummel-Ziedins, Kathleen, Key, Nigel S.
Publicado 2013

Use of thrombin generation assay to personalize treatment of breakthrough bleeds in a patient with hemophilia and inhibitors receiving prophylaxis with emicizumab

por Dargaud, Yesim, Lienhart, Anne, Janbain, Maissaa, Le Quellec, Sandra, Enjolras, Nathalie, Negrier, Claude
Publicado en Haematologica (2018)

Impaired factor XIII activation in patients with congenital afibrinogenemia

por Bridey, Françoise, Négrier, Claude, Duval, Cedric, Ariëns, Robert, de Moerloose, Philippe, Casini, Alessandro
Publicado en Haematologica (2019)

Reccurrent F8 Intronic Deletion Found in Mild Hemophilia A Causes Alu Exonization

por Jourdy, Yohann, Janin, Alexandre, Fretigny, Mathilde, Lienhart, Anne, Négrier, Claude, Bozon, Dominique, Vinciguerra, Christine
Publicado en Am J Hum Genet (2018)

Origins, Development, Current Challenges and Future Directions with Activated Prothrombin Complex Concentrate for the Treatment of Patients with Congenital Haemophilia with Inhibit...

por Brackmann, Hans H., Schramm, Wolfgang, Oldenburg, Johannes, Cano, Viridiana, Turecek, Peter L., Négrier, Claude
Publicado en Hamostaseologie (2020)

MDA-9/Syntenin Is Essential for Factor VIIa-induced Signaling, Migration, and Metastasis in Melanoma Cells

por Aissaoui, Hanaa, Prévost, Célia, Boucharaba, Ahmed, Sanhadji, Kamel, Bordet, Jean-Claude, Négrier, Claude, Boukerche, Habib
Publicado en J Biol Chem (2015)

MDA-9/Syntenin is essential for factor VIIa-induced signaling, migration, and metastasis in melanoma cells.

por Aissaoui, Hanaa, Prévost, Célia, Boucharaba, Ahmed, Sanhadji, Kamel, Bordet, Jean-Claude, Négrier, Claude, Boukerche, Habib
Publicado en J Biol Chem (2015)

Decreased Bleeding Rates in Patients with Hemophilia A Switching from Standard-Half-Life FVIII to BAY 94-9027 Prophylaxis

por Mancuso, Maria Elisa, Reding, Mark T., Negrier, Claude, Kerlin, Bryce A., Rangarajan, Savita, Simpson, Mindy L.
Publicado en Thromb Haemost (2021)

Alpha Cyano-4-Hydroxy-3-Methoxycinnamic Acid Inhibits Proliferation and Induces Apoptosis in Human Breast Cancer Cells

por Hamdan, Lamia, Arrar, Zoheir, Al Muataz, Yacoub, Suleiman, Lutfi, Négrier, Claude, Mulengi, Joseph Kajima, Boukerche, Habib
Publicado 2013

Why patients with THBD c.1611C>A (p.Cys537X) nonsense mutation have high levels of soluble thrombomodulin?

por Jourdy, Yohann, Enjolras, Nathalie, Le Quellec, Sandra, Bordet, Jean Claude, Négrier, Claude, Vinciguerra, Christine, Dargaud, Yesim
Publicado en PLoS One (2017)

Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients

por Santagostino, Elena, Negrier, Claude, Klamroth, Robert, Tiede, Andreas, Pabinger-Fasching, Ingrid, Voigt, Christine, Jacobs, Iris, Morfini, Massimo
Publicado 2012

A French multicenter randomised trial comparing two dose-regimens of prothrombin complex concentrates in urgent anticoagulation reversal

por Kerebel, Delphine, Joly, Luc-Marie, Honnart, Didier, Schmidt, Jeannot, Galanaud, Damien, Negrier, Claude, Kursten, Friedrich, Coriat, Pierre
Publicado 2013

Global Post-Authorization Safety Surveillance Study: real-world data on prophylaxis and on-demand treatment using FEIBA (an activated prothrombin complex concentrate)

por Negrier, Claude, Voisin, Sophie, Baghaei, Fariba, Numerof, Robert, Novack, Aaron, Doralt, Jennifer E., Romanov, Vadim, Gringeri, Alessandro
Publicado en Blood Coagul Fibrinolysis (2016)

Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study

por Schmitt, Christophe, Adamkewicz, Joanne I., Xu, Jin, Petry, Claire, Catalani, Olivier, Young, Guy, Negrier, Claude, Callaghan, Michael U., Levy, Gallia G.
Publicado en Thromb Haemost (2021)

Hypofibrinolytic state and high thrombin generation may play a major role in SARS‐COV2 associated thrombosis

por Nougier, Christophe, Benoit, Remi, Simon, Marie, Desmurs‐Clavel, Helene, Marcotte, Guillaume, Argaud, Laurent, David, Jean Stephane, Bonnet, Aurelie, Negrier, Claude, Dargaud, Yesim
Publicado en J Thromb Haemost (2020)

Characterization of an autosomal dominant bleeding disorder caused by a thrombomodulin mutation

por Dargaud, Yesim, Scoazec, Jean Yves, Wielders, Simone J. H., Trzeciak, Christine, Hackeng, Tilman M., Négrier, Claude, Hemker, H. Coenraad, Lindhout, Theo, Castoldi, Elisabetta
Publicado en Blood (2015)